Dominik Fröhlich1, Alexandra K Suchowerska2, Ziggy H T Spencer3, Georg von Jonquieres4, Claudia B Klugmann5, Andre Bongers6, Fabien Delerue7, Holly Stefen8, Lars M Ittner9, Thomas Fath10, Gary D Housley11, Matthias Klugmann12. 1. Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: d.frohlich@unsw.edu.au. 2. Neurodegenerative and Repair Unit, School of Medical Science, UNSW Sydney, NSW 2052, Australia. Electronic address: a.suchowerska@unsw.edu.au. 3. Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: ziggy@unsw.edu.au. 4. Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: g.jonquieres@unsw.edu.au. 5. Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: c.klugmann@unsw.edu.au. 6. Biomedical Resources Imaging Laboratory, UNSW Sydney, NSW 2052, Australia. Electronic address: a.bongers@unsw.edu.au. 7. Transgenic Animal Unit, Mark Wainwright Analytical Centre, UNSW Sydney, NSW 2052, Australia. Electronic address: fabien.delerue@unsw.edu.au. 8. Neurodegenerative and Repair Unit, School of Medical Science, UNSW Sydney, NSW 2052, Australia. Electronic address: h.stefen@unsw.edu.au. 9. Transgenic Animal Unit, Mark Wainwright Analytical Centre, UNSW Sydney, NSW 2052, Australia; Dementia Research Unit, School of Medical Science, UNSW Sydney, NSW 2052, Australia; Neuroscience Research Australia, Sydney, NSW 2031, Australia. Electronic address: l.ittner@unsw.edu.au. 10. Neurodegenerative and Repair Unit, School of Medical Science, UNSW Sydney, NSW 2052, Australia. Electronic address: t.fath@unsw.edu.au. 11. Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: g.housley@unsw.edu.au. 12. Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: m.klugmann@unsw.edu.au.
Abstract
BACKGROUND: The recently diagnosed leukodystrophy Hypomyelination with Brain stem and Spinal cord involvement and Leg spasticity (HBSL) is caused by mutations of the cytoplasmic aspartyl-tRNA synthetase geneDARS. The physiological role of DARS in translation is to accurately pair aspartate with its cognate tRNA. Clinically, HBSL subjects show a distinct pattern of hypomyelination and develop progressive leg spasticity, variable cognitive impairment and epilepsy. To elucidate the underlying pathomechanism, we comprehensively assessed endogenous DARS expression in mice. Additionally, aiming at creating the first mammalian HBSL model, we genetically engineered and phenotyped mutant mice with a targetedDarslocus. RESULTS: DARS, although expressed in all organs, shows a distinct expression pattern in the adult brain with little immunoreactivity in macroglia but enrichment in neuronal subpopulations of the hippocampus, cerebellum, and cortex. Within neurons, DARS is mainly located in the cell soma where it co-localizes with other components of the translation machinery. Intriguingly, DARS is also present along neurites and at synapses, where it potentially contributes to local protein synthesis.Dars-null mice are not viable and die before embryonic day 11. Heterozygous mice with only one functionalDarsallele display substantially reduced DARS levels in the brain; yet these mutants show no gross abnormalities, including unchanged motor performance. However, we detected reduced pre-pulse inhibition of the acoustic startle response indicating dysfunction of attentional processing inDars+/-mice. CONCLUSIONS: Our results, for the first time, show an in-depth characterization of the DARS tissue distribution in mice, revealing surprisingly little uniformity across brain regions or between the major neural cell types. The complete loss of DARS function is not tolerated in mice suggesting that the identified HBSL mutations in humans retain some residual enzyme activity. The mild phenotype of heterozygousDars-null carriers indicates that even partial restoration of DARS levels would be therapeutically relevant. Despite the fact that they do not resemble the full spectrum of clinical symptoms, the robust pre-pulse inhibition phenotype ofDars+/-mice will be instrumental for future preclinical therapeutic efficacy studies. In summary, our data is an important contribution to a better understanding of DARS function and HBSL pathology. Copyright Â
BACKGROUND: The recently diagnosed leukodystrophy Hypomyelination with Brain stem and Spinal cord involvement and Leg spasticity (HBSL) is caused by mutations of the cytoplasmic aspartyl-tRNA synthetase geneDARS. The physiological role of DARS in translation is to accurately pair aspartate with its cognate tRNA. Clinically, HBSL subjects show a distinct pattern of hypomyelination and develop progressive leg spasticity, variable cognitive impairment and epilepsy. To elucidate the underlying pathomechanism, we comprehensively assessed endogenous DARS expression in mice. Additionally, aiming at creating the first mammalianHBSL model, we genetically engineered and phenotyped mutant mice with a targetedDarslocus. RESULTS:DARS, although expressed in all organs, shows a distinct expression pattern in the adult brain with little immunoreactivity in macroglia but enrichment in neuronal subpopulations of the hippocampus, cerebellum, and cortex. Within neurons, DARS is mainly located in the cell soma where it co-localizes with other components of the translation machinery. Intriguingly, DARS is also present along neurites and at synapses, where it potentially contributes to local protein synthesis.Dars-null mice are not viable and die before embryonic day 11. Heterozygous mice with only one functionalDarsallele display substantially reduced DARS levels in the brain; yet these mutants show no gross abnormalities, including unchanged motor performance. However, we detected reduced pre-pulse inhibition of the acoustic startle response indicating dysfunction of attentional processing inDars+/-mice. CONCLUSIONS: Our results, for the first time, show an in-depth characterization of the DARS tissue distribution in mice, revealing surprisingly little uniformity across brain regions or between the major neural cell types. The complete loss of DARS function is not tolerated in mice suggesting that the identified HBSL mutations in humans retain some residual enzyme activity. The mild phenotype of heterozygousDars-null carriers indicates that even partial restoration of DARS levels would be therapeutically relevant. Despite the fact that they do not resemble the full spectrum of clinical symptoms, the robust pre-pulse inhibition phenotype ofDars+/-mice will be instrumental for future preclinical therapeutic efficacy studies. In summary, our data is an important contribution to a better understanding of DARS function and HBSL pathology. Copyright Â
Authors: Jamie A Abbott; Rebecca Meyer-Schuman; Vincenzo Lupo; Shawna Feely; Inès Mademan; Stephanie N Oprescu; Laurie B Griffin; M Antonia Alberti; Carlos Casasnovas; Sharon Aharoni; Lina Basel-Vanagaite; Stephan Züchner; Peter De Jonghe; Jonathan Baets; Michael E Shy; Carmen Espinós; Borries Demeler; Anthony Antonellis; Christopher Francklyn Journal: Hum Mutat Date: 2017-12-26 Impact factor: 4.878
Authors: Matthias Klugmann; Elizabeth Kalotay; Fabien Delerue; Lars M Ittner; Andre Bongers; Josephine Yu; Margaret J Morris; Gary D Housley; Dominik Fröhlich Journal: Neurochem Res Date: 2022-03-31 Impact factor: 4.414
Authors: Alexandra K Suchowerska; Sandra Fok; Holly Stefen; Peter W Gunning; Edna C Hardeman; John Power; Thomas Fath Journal: Front Cell Neurosci Date: 2017-12-22 Impact factor: 5.505
Authors: Dominik Fröhlich; Marisa I Mendes; Andrew J Kueh; Andre Bongers; Marco J Herold; Gajja S Salomons; Gary D Housley; Matthias Klugmann Journal: Front Cell Neurosci Date: 2021-01-20 Impact factor: 5.505
Authors: Georg von Jonquieres; Ziggy H T Spencer; Benjamin D Rowlands; Claudia B Klugmann; Andre Bongers; Anne E Harasta; Kristina E Parley; Jennie Cederholm; Orla Teahan; Russell Pickford; Fabien Delerue; Lars M Ittner; Dominik Fröhlich; Catriona A McLean; Anthony S Don; Miriam Schneider; Gary D Housley; Caroline D Rae; Matthias Klugmann Journal: Acta Neuropathol Date: 2017-11-07 Impact factor: 17.088
Authors: Dominik Fröhlich; Alexandra K Suchowerska; Carola Voss; Ruojie He; Ernst Wolvetang; Georg von Jonquieres; Cas Simons; Thomas Fath; Gary D Housley; Matthias Klugmann Journal: Front Mol Neurosci Date: 2018-03-20 Impact factor: 5.639